论文信息 - Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial - 字舞流文

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

Inge Christoffer Olsen | J. Lampa | M. Nurmohamed | M. Kapetanovic | A. Rudin | M. Østergaard | T. Uhlig | T. Sokka | D. Nordström | B. Gudbjornsson | R. V. van Vollenhoven | T. Rannio | K. Hørslev-Petersen | A. Kastbom | F. Faustini | M. Hetland | T. Lorenzen | I. Gjertsson | H. Lindegaard | E. Haavardsholm | G. Bakland | G. Grondal | S. A. Just | S. Krabbe | D. Glinatsi | P. Bøyesen | J. Lindqvist | A. Aga | L. Uhrenholt | D. Vedder | A. Söderbergh | L. Ørnbjerg | E. Brodin | P. Larsson | O. Hendricks | P. Parmanne | M. Heiberg | K. Lend | M. Rizk | D. Stevens | M. K. Ljoså | M. K. Ljosa | Cagnotto Giovanni | J. Back | Emma Grenholm | Trine Bay Laurbjerg